September 2026
M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30

$Jignesh Patel: Call for Papers on Safer IV Unfractionated Heparin Use$

Jignesh Patel/LinkedIn

Sep 26, 2026, 07:23

Jignesh Patel: Call for Papers on Safer IV Unfractionated Heparin Use

Jignesh Patel, Reader and Honorary Consultant Pharmacist in Anticoagulation at King’s College London, shared a post on LinkedIn:

“Call for papers – improving the safety and efficacy of intravenous unfractionated heparin infusions in clinical practice

Pleased to be co-leading as guest editor with Dr Nienke van Rein a theme issue for the British Journal of Clinical Pharmacology focused on improving the safety and efficacy of intravenous unfractionated heparin infusions in clinical practice.

Unfractionated heparin (UFH) was the first anticoagulant to become available in clinical practice for the prevention and treatment of thrombosis and is included on the WHO list of essential medications as one of the most critical and effective medications necessary to meet the needs of a healthcare system.

However, UFH is a leading cause of anticoagulation related adverse drug events in health systems around the world. UFH is classed as one of six drugs most frequently involved in serious medication events and is classified by the Institute for Safe Medication Practices as a ‘high-alert’ medication.

The aims of this special issue are to:

Consolidate research and best practice initiatives associated with the use of IV UFH infusions
Highlight research which addresses dosing and monitoring strategies for IV UFH infusions
Report on how IV UFH infusion use can be minimised through alternative anticoagulant use, to manage risk
Describe UFH antidote dosage strategies in specific situations (e.g. bleeding or at the conclusion of cardiopulmonary bypass)

Topics of interest for this call for papers include but are not restricted to the following:

Anticoagulation stewardship initiatives which improve the safe use of intravenous unfractionated heparin infusions in clinical practice
Dosing and monitoring issues associated with intravenous unfractionated heparin infusions;

Strategies being utilised to minimise the use of intravenous unfractionated heparin infusions in practice

Use of AI in the dosing of IV UFH infusions
The safe integration of IV UFH dosing and monitoring protocols into electronic prescribing systems
Educational initiatives used to manage IV UFH risks in clinical practice
Protocol standardisation leading to safer and consistent use of IV UFH infusions
IV UFH infusion use in special populations (e.g. paediatrics, ecmo, liver cirrhosis, CVVH)
Monitoring assays for IV UFH infusions
Point of care testing for IV UFH infusions
UFH antidote dosage and administration.

Deadline for submissions: Friday, 30 July 2027.”

Stay updated with Hemostasis Today.